Clinuvel Pharmaceuticals (CUV.AX) Earnings Analysis
Clinuvel Pharmaceuticals (CUV.AX) next reports earnings on 2026-09-01, consensus EPS 0.4534 AUD. Last quarter (2026-02-25) it missed with EPS 0.2063 AUD vs 0.2926 AUD est (-29.5%). It has beaten estimates in 3/4 recent quarters (75%). Trailing P/E 15.31.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does CUV.AX next report earnings?
| Next earnings date | 2026-09-01 |
|---|---|
| Consensus EPS estimate | 0.4534 AUD |
| Revenue estimate | 0.06B |
CUV.AX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-25 | 0.2063 AUD | 0.2926 AUD | -29.5% | Miss |
| 2025-08-27 | 0.438 AUD | 0.28 AUD | +56.4% | Beat |
| 2025-02-26 | 0.28 AUD | 0.217 AUD | +29% | Beat |
| 2024-08-29 | 0.4894 AUD | 0.4406 AUD | +11.1% | Beat |
Beat rate: 3/4 (75%) over reported quarters with consensus data.
CUV.AX valuation and analyst view
| Trailing P/E | 15.31 |
|---|---|
| Trailing EPS | 0.64876 AUD |
| Price / book | 2.00 |
| Dividend yield | 0.50% |
| Market cap | 0.50B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Clinuvel Pharmaceuticals (CUV.AX)'s next earnings date?
Clinuvel Pharmaceuticals is next scheduled to report on 2026-09-01, with a consensus EPS estimate of 0.4534 AUD and revenue estimate of 0.06B.
Did CUV.AX beat earnings last quarter?
In its 2026-02-25 report, CUV.AX posted EPS of 0.2063 AUD versus a 0.2926 AUD estimate — a miss of 29.5%.
What is CUV.AX's earnings track record?
Over the last 4 reported quarters with consensus data, CUV.AX beat estimates 3 times (75%).
What is CUV.AX's current P/E ratio and EPS?
CUV.AX trades at a trailing P/E of 15.31 on trailing EPS of 0.6487595650496747 AUD.
What do analysts rate CUV.AX?
CUV.AX has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.